Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
-
Multicenter Study
Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.
The incidence of mesothelioma is rising. First-line cisplatin and pemetrexed confers a survival benefit, with a median progression-free survival (PFS) of 5.7 months. Sorafenib inhibits tyrosine kinases, including receptors for vascular endothelial growth factor, which are implicated in mesothelioma pathogenesis by preclinical and clinical data. ⋯ Sorafenib is well tolerated in patients with mesothelioma after completion of platinum-containing chemotherapy. PFS of sorafenib compares favorably with that reported for other targeted agents, and suggests moderate activity in this disease.